Hemangiol

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

propranolol hidroklorid

Available from:

Pierre Fabre Medicament

ATC code:

C07AA05

INN (International Name):

propranolol

Therapeutic group:

Beta blokirajuća sredstva

Therapeutic area:

hemangiom

Therapeutic indications:

Hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: , Life- or function-threatening haemangioma,, Ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, Haemangioma with a risk of permanent scars or disfigurement. , It is to be initiated in infants aged 5 weeks to 5 months.

Product summary:

Revision: 6

Authorization status:

odobren

Authorization date:

2014-04-23

Patient Information leaflet

                                21
B. UPUTA O LIJEKU
22
UPUTA O LIJEKU: INFORMACIJE ZA KORISNIKA
HEMANGIOL 3,75 MG/ML ORALNA OTOPINA
propranolol
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO VAŠE DIJETE POČNE
UZIMATI OVAJ LIJEK JER SADRŽI VAŽNE
PODATKE.
•
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
•
Ako imate dodatnih pitanja, obratite se liječniku, ljekarniku ili
medicinskoj sestri.
•
Ovaj je lijek propisan samo za Vaše dijete. Nemojte ga davati
drugima. Može im naškoditi, čak i
ako su njihovi znakovi bolesti jednaki onima u Vašeg djeteta.
•
Ako primijetite bilo koju nuspojavu kod Vašeg djeteta, potrebno je
obavijestiti liječnika,
ljekarnika ili medicinsku sestru. To uključuje i svaku moguću
nuspojavu koja nije navedena u
ovoj uputi. Pogledajte dio 4.
ŠTO SE NALAZI U OVOJ UPUTI
1.
Što je HEMANGIOL i za što se koristi
2.
Što morate znati prije nego Vaše dijete počne primati HEMANGIOL
3.
Kako davati HEMANGIOL Vašem djetetu
4.
Moguće nuspojave
5.
Kako čuvati HEMANGIOL
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE HEMANGIOL I ZA ŠTO SE KORISTI
ŠTO JE HEMANGIOL
Naziv Vašeg lijeka je HEMANGIOL. Djelatni sastojak je propranolol.
Propranolol pripada skupini lijekova poznatih kao beta-blokatori.
ZA ŠTO SE KORISTI
Ovaj lijek se koristi za liječenje bolesti nazvane hemangiom.
Hemangiom je nakupina viška krvnih
žila koje oblikuju kvržicu unutar ili ispod kože. Hemangiom može
biti površinski ili duboki. On se
ponekad naziva „znak jagode“ jer površina hemangioma pomalo
izgleda poput jagode.
HEMANGIOL se započinje primjenjivati kod dojenčadi u dobi od 5
tjedana do 5 mjeseci, kada:
-
smještaj i/ili proširenost lezija ugrožava život ili funkciju
(može oštetiti vitalne organe ili osjetila
kao što su vid ili sluh);
-
hemangiom je ulceriran (s ranama na koži koje ne zacjeljuju) i bolan
i/ili ne odgovara na
jednostavne mjere njege rane;
-
postoji rizik od trajnih ožiljaka ili izobličavanja.
2.
ŠTO MORATE ZNATI PRIJE NEGO VAŠE DIJETE POČNE PRIMATI HEMANGIOL
_ _
NEMOJTE PRIMJ
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1
NAZIV LIJEKA
HEMANGIOL 3,75 mg/ml oralna otopina
2
KVALITATIVNI I KVANTITATIVNI SASTAV
1 ml otopine sadrži 4,28 mg propranololklorida što odgovara 3,75 mg
propranolola u obliku baze.
Pomoćna tvar s poznatim učinkom:
1 ml otopine sadrži
propilenglikol
………………………………………………….
2,60 mg.
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3
FARMACEUTSKI OBLIK
Oralna otopina.
Bistra, bezbojna do blago žuta oralna otopina, s voćnim mirisom.
4
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
HEMANGIOL je indiciran za liječenje proliferirajućeg infantilnog
hemangioma koji zahtijeva
sistemsku terapiju:
• hemangiom koji ugrožava život ili funkciju,
• ulcerirani hemangiom s bolovima i/ili izostankom odgovora na
jednostavne mjere njege rane,
• hemangiom s opasnošću od trajnih o
ž
iljaka ili izobličavanja.
Primjenu treba započeti kod dojenčadi u dobi od 5 tjedana do 5
mjeseci (vidjeti dio 4.2).
4.2
DOZIRANJE I NAČIN PRIMJENE
_ _
Liječenje HEMANGIOL-om trebaju započeti liječnici koji imaju
iskustvo u dijagnostici, liječenju i
vođenju infantilnog hemangioma, u kontroliranom kliničkom okruženju
u kojem stoje na raspolaganju
odgovarajuće mogućnosti za zbrinjavanje nuspojava, uključujući i
one koje zahtijevaju hitne mjere.
_ _
_ _
Doziranje
Doziranje je izraženo u propranololu u obliku baze.
Preporučena početna doza je 1 mg/kg/dan koja je podijeljena u dvije
odvojene doze od 0,5 mg/kg.
Preporučuje se povećati dozu do terapijske doze pod liječničkim
nadzorom, na sljedeći način:
1 mg/kg/dan tijekom 1 tjedna, zatim 2 mg/kg/dan tijekom 1 tjedna, a
zatim 3 mg/kg/dan kao doza
održavanja.
Terapijska doza je 3 mg/kg/dan, koja se treba primijeniti u 2 odvojene
doze od 1,5 mg/kg, jednu
ujutro, a jednu u kasno poslijepodne, s vremenskim razmakom od
najmanje 9 sati između dva unosa.
HEMANGIOL treba dati tijekom ili neposredno nakon hranjenja kako bi se
izbjegao rizik od
hipoglikemije.
Ako dijete ne jede dovoljno ili povra
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 09-02-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 09-02-2023
Public Assessment Report Public Assessment Report Bulgarian 19-05-2014
Patient Information leaflet Patient Information leaflet Spanish 09-02-2023
Public Assessment Report Public Assessment Report Spanish 19-05-2014
Patient Information leaflet Patient Information leaflet Czech 09-02-2023
Public Assessment Report Public Assessment Report Czech 19-05-2014
Patient Information leaflet Patient Information leaflet Danish 09-02-2023
Public Assessment Report Public Assessment Report Danish 19-05-2014
Patient Information leaflet Patient Information leaflet German 09-02-2023
Public Assessment Report Public Assessment Report German 19-05-2014
Patient Information leaflet Patient Information leaflet Estonian 09-02-2023
Public Assessment Report Public Assessment Report Estonian 19-05-2014
Patient Information leaflet Patient Information leaflet Greek 09-02-2023
Public Assessment Report Public Assessment Report Greek 19-05-2014
Patient Information leaflet Patient Information leaflet English 09-02-2023
Public Assessment Report Public Assessment Report English 19-05-2014
Patient Information leaflet Patient Information leaflet French 09-02-2023
Public Assessment Report Public Assessment Report French 19-05-2014
Patient Information leaflet Patient Information leaflet Italian 09-02-2023
Public Assessment Report Public Assessment Report Italian 19-05-2014
Patient Information leaflet Patient Information leaflet Latvian 09-02-2023
Public Assessment Report Public Assessment Report Latvian 19-05-2014
Patient Information leaflet Patient Information leaflet Lithuanian 09-02-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 09-02-2023
Public Assessment Report Public Assessment Report Lithuanian 19-05-2014
Patient Information leaflet Patient Information leaflet Hungarian 09-02-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 09-02-2023
Public Assessment Report Public Assessment Report Hungarian 19-05-2014
Patient Information leaflet Patient Information leaflet Maltese 09-02-2023
Public Assessment Report Public Assessment Report Maltese 19-05-2014
Patient Information leaflet Patient Information leaflet Dutch 09-02-2023
Public Assessment Report Public Assessment Report Dutch 19-05-2014
Patient Information leaflet Patient Information leaflet Polish 09-02-2023
Public Assessment Report Public Assessment Report Polish 19-05-2014
Patient Information leaflet Patient Information leaflet Portuguese 09-02-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 09-02-2023
Public Assessment Report Public Assessment Report Portuguese 19-05-2014
Patient Information leaflet Patient Information leaflet Romanian 09-02-2023
Public Assessment Report Public Assessment Report Romanian 19-05-2014
Patient Information leaflet Patient Information leaflet Slovak 09-02-2023
Public Assessment Report Public Assessment Report Slovak 19-05-2014
Patient Information leaflet Patient Information leaflet Slovenian 09-02-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 09-02-2023
Public Assessment Report Public Assessment Report Slovenian 19-05-2014
Patient Information leaflet Patient Information leaflet Finnish 09-02-2023
Public Assessment Report Public Assessment Report Finnish 19-05-2014
Patient Information leaflet Patient Information leaflet Swedish 09-02-2023
Public Assessment Report Public Assessment Report Swedish 19-05-2014
Patient Information leaflet Patient Information leaflet Norwegian 09-02-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 09-02-2023
Patient Information leaflet Patient Information leaflet Icelandic 09-02-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 09-02-2023

Search alerts related to this product

View documents history